Meeting
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Sustained, cell-intrinsic versus intermittent, cell-extrinsic checkpoint blockade in solid tumor CAR T-cell therapy.
Authors
Camille Linot
Memorial Sloan Kettering Cancer Center, New York, NY
Camille Linot, Jasmeen Saini, Prasad S. Adusumilli
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Cell Therapies
Citation
J Clin Oncol 38, 2020 (suppl 5; abstr 16)
Abstract #
16
Poster Bd #
B10
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
Activation of central/effector memory T cells in advanced gastric cancer patients treated with antiprogrammed death-1 antibody.
First Author: Hirofumi Ohmura
Poster
2023 ASCO Annual Meeting
Exploring the potential of combination immune checkpoint strategies in non-small cell lung cancer (NSCLC).
First Author: Aakash Desai
Poster
2022 ASCO Annual Meeting
Identification of super-exhausted T cells: A novel population predictive of response to immunotherapy.
First Author: Florent Peyraud
Poster
2020 ASCO Virtual Scientific Program
Phase I study of CRISPR-engineered CAR-T cells with PD-1 inactivation in treating mesothelin-positive solid tumors.
First Author: Zhenguang Wang